What it’s for
- Experimental longevity use
- Topical treatment of androgenetic hair loss
Personal amounts and schedules belong to the individual protocol item; there is no established human longevity dose.
A weakly estrogenic form of estradiol studied in mice for ageing and used topically for hair loss.
Purpose, evidence and practical considerations.
Personal amounts and schedules belong to the individual protocol item; there is no established human longevity dose.
Male mice given 17α-estradiol lived longer in two Interventions Testing Program studies, with no benefit in females. No human trial has tested it for ageing, and long-term human safety is not established.
Confidence: weak
Human safety data for systemic or long-term use are very limited. It is a steroid hormone and may have estrogenic or anti-androgenic effects, including on fertility, breast tissue and sex-hormone levels. Use requires a prescriber and monitoring.
17α-estradiol binds classical estrogen receptors much more weakly than 17β-estradiol. In male mice it alters nutrient-sensing and metabolic pathways and lowers body weight and inflammation markers; how much of this applies to people is unknown.
Regulatory status: Not approved as a longevity medicine. A topical alfatradiol solution is sold for hair loss in some European countries; other preparations are compounded on prescription.
The evidence on this page does not automatically apply to:
How people use it, with their schedules, context and original sources.
8 mg a week, transdermal (protocol.bryanjohnson.com, archived Oct 2023) · Weekly, as listed in October 2023
Dose and schedule patterns reported in public protocols; these are observations, not prescribing advice. Private and hidden usage is excluded.
1 public example — useful context, not a reliable distribution.
1 public example — useful context, not a reliable distribution.
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.